Company profile
Bottneuro AG
Bottneuro, a startup from the University of Basel on the Novartis campus, provides a fully personalized neurostimulation therapy based on each patient's MRI data. Our device is registered with SWISSMEDIC, MHRA, and EUDAMED as a Custom Made Device, allowing neurologists and psychiatrists in Switzerland, the UK, and the EU to prescribe it for Alzheimer's, stroke, epilepsy, depression, and psychiatric disorders. We've completed the first human study, and we're now treating first patients in Switzerland.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
